FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255136274> ?p ?o ?g. }

• W2255136274 abstract "Background: The Pharmacy Quality Alliance (PQA) has endorsed adherence to non-warfarin anticoagulant agents as a new performance measure, but it has not yet been adopted by the Medicare Part D Star Ratings program. Medication adherence and other pharmacy measures are currently weighted at nearly half of a plan’s Star rating. Two, 3, 4 and 5 Star ratings are based on achievement of adherence threshold levels (e.g. 74%, 79%, 82%, and 85% for oral diabetes medications). Inclusion of the adherence to non-warfarin anticoagulant measure in the Star Ratings program would increase a plan’s incentives to improve patient adherence. Objective: To assess the adherence to medication of patients who used the target-specific oral anticoagulants (TSOAC) rivaroxaban, dabigatran, or apixaban in 2013 based on the PQA’s adherence to non-warfarin anticoagulant agent measure. Methods: Healthcare claims from the Humana database during the year of 2013 were analyzed. Adult patients with ≥2 dispensings of TSOAC agents in 2013, at least 180 days apart between two TSOAC dispensings in 2013 (a criterion to include chronic users), and with at least 60 days of supply were identified. Patients were observed from the first rivaroxaban, dabigatran, or apixaban dispensing in 2013 up to end of insurance coverage or 12/31/2013. Patients who filled prescriptions for warfarin or other injectable anticoagulants during the follow-up were excluded. The PQA measure was calculated as the percentage of patients who had a proportion of days covered (PDC) ≥80% during the follow-up. PQA measures were evaluated for a) the index TSOAC agent and b) allowing switches to other TSOAC agents (i.e., a patient still counted as using therapy after a switch). Comparisons of PQA measures were made between the rivaroxaban group and each of the other two groups using chi-squared tests. Results: A total of 9,948 TSOAC users (rivaroxaban: n=4,194, dabigatran: n=5,489, apixaban: n=265) were identified; mean age was between 75-77 years; 49.7%, 45.7%, and 43.4% were female, respectively. The mean follow-up period was 308, 329, and 247 days for rivaroxaban, dabigatran, and apixaban users, respectively. For rivaroxaban users, the proportion of patients with a PDC ≥0.8 (PQA measure) calculated using the index TSOAC agent at 75.4% was significantly higher compared to dabigatran users (67.6%; P<.001) and trending higher compared to apixaban users (70.6%; P=0.076). When allowing switches to other TSOAC agents in the PQA measure, rivaroxaban users had a significantly higher PQA measure at 76.9% compared to both dabigatran (72.9%; P<.001) and apixaban (71.3%; P=0.037) users. Conclusion: Based on the PQA’s adherence to non-warfarin anticoagulant agent measure, rivaroxaban users were found to have a higher adherence compared to dabigatran and apixaban users. Healthcare providers should consider the impact of anticoagulation selection on achieving quality metrics." @default.
• W2255136274 created "2016-06-24" @default.
• W2255136274 creator A5017834828 @default.
• W2255136274 creator A5019269759 @default.
• W2255136274 creator A5061998147 @default.
• W2255136274 creator A5070635016 @default.
• W2255136274 creator A5077613669 @default.
• W2255136274 creator A5083091499 @default.
• W2255136274 creator A5084358901 @default.
• W2255136274 creator A5087850384 @default.
• W2255136274 date "2015-05-01" @default.
• W2255136274 modified "2023-09-26" @default.
• W2255136274 title "Abstract 366: Pharmacy Quality Alliance Measure: Adherence to Non-Warfarin Oral Anticoagulant Medication" @default.
• W2255136274 doi "https://doi.org/10.1161/circoutcomes.8.suppl_2.366" @default.
• W2255136274 hasPublicationYear "2015" @default.
• W2255136274 type Work @default.
• W2255136274 sameAs 2255136274 @default.
• W2255136274 citedByCount "2" @default.
• W2255136274 countsByYear W22551362742015 @default.
• W2255136274 countsByYear W22551362742018 @default.
• W2255136274 crossrefType "journal-article" @default.
• W2255136274 hasAuthorship W2255136274A5017834828 @default.
• W2255136274 hasAuthorship W2255136274A5019269759 @default.
• W2255136274 hasAuthorship W2255136274A5061998147 @default.
• W2255136274 hasAuthorship W2255136274A5070635016 @default.
• W2255136274 hasAuthorship W2255136274A5077613669 @default.
• W2255136274 hasAuthorship W2255136274A5083091499 @default.
• W2255136274 hasAuthorship W2255136274A5084358901 @default.
• W2255136274 hasAuthorship W2255136274A5087850384 @default.
• W2255136274 hasConcept C104863432 @default.
• W2255136274 hasConcept C126322002 @default.
• W2255136274 hasConcept C1862650 @default.
• W2255136274 hasConcept C2426938 @default.
• W2255136274 hasConcept C2776291444 @default.
• W2255136274 hasConcept C2776301958 @default.
• W2255136274 hasConcept C2778205648 @default.
• W2255136274 hasConcept C2778661090 @default.
• W2255136274 hasConcept C2778810321 @default.
• W2255136274 hasConcept C2778858636 @default.
• W2255136274 hasConcept C2779161974 @default.
• W2255136274 hasConcept C2780638905 @default.
• W2255136274 hasConcept C512399662 @default.
• W2255136274 hasConcept C71924100 @default.
• W2255136274 hasConcept C98274493 @default.
• W2255136274 hasConceptScore W2255136274C104863432 @default.
• W2255136274 hasConceptScore W2255136274C126322002 @default.
• W2255136274 hasConceptScore W2255136274C1862650 @default.
• W2255136274 hasConceptScore W2255136274C2426938 @default.
• W2255136274 hasConceptScore W2255136274C2776291444 @default.
• W2255136274 hasConceptScore W2255136274C2776301958 @default.
• W2255136274 hasConceptScore W2255136274C2778205648 @default.
• W2255136274 hasConceptScore W2255136274C2778661090 @default.
• W2255136274 hasConceptScore W2255136274C2778810321 @default.
• W2255136274 hasConceptScore W2255136274C2778858636 @default.
• W2255136274 hasConceptScore W2255136274C2779161974 @default.
• W2255136274 hasConceptScore W2255136274C2780638905 @default.
• W2255136274 hasConceptScore W2255136274C512399662 @default.
• W2255136274 hasConceptScore W2255136274C71924100 @default.
• W2255136274 hasConceptScore W2255136274C98274493 @default.
• W2255136274 hasIssue "suppl_2" @default.
• W2255136274 hasLocation W22551362741 @default.
• W2255136274 hasOpenAccess W2255136274 @default.
• W2255136274 hasPrimaryLocation W22551362741 @default.
• W2255136274 hasRelatedWork W1757837840 @default.
• W2255136274 hasRelatedWork W1980555552 @default.
• W2255136274 hasRelatedWork W1980640915 @default.
• W2255136274 hasRelatedWork W2065357039 @default.
• W2255136274 hasRelatedWork W2167924766 @default.
• W2255136274 hasRelatedWork W2255136274 @default.
• W2255136274 hasRelatedWork W2741829680 @default.
• W2255136274 hasRelatedWork W2908436399 @default.
• W2255136274 hasRelatedWork W2981617427 @default.
• W2255136274 hasRelatedWork W3202697683 @default.
• W2255136274 hasVolume "8" @default.
• W2255136274 isParatext "false" @default.
• W2255136274 isRetracted "false" @default.
• W2255136274 magId "2255136274" @default.
• W2255136274 workType "article" @default.